Fourth Asian Pacific Conference: Perspectives in Lung Cancer

3. 9. 2010 - 4. 9. 2010, Hyatt Regency Hong Kong, Sha Tin, Hong Kong, China

Aktivní účast

Registrace

Program konference

Friday, 3 September 2010

8:15
Opening remarks

Session I: State-of-the-art in surgery
8:30
The art of radical surgery
David Harpole, MD

8:55
The art of minimal invasive surgery
Masahiro Tsuboi, MD

9:20
EBUS versus mediastinoscopy
Speaker invited

Session II: Tobacco and carcinogenesis
9:45
Tobacco control in Asia
Speaker invited

10:20
Carcinogenesis of lung cancer: Smoker vs non-smoker
Speaker invited

10:45
Coffee break

Session III: State-of-the-art radiotherapy
11:15
Novel radiotherapy technology
Speaker invited

11:40
Stereotactic radiotherapy for resectable lung cancer
Speaker invited

12:05 Stereotactic and respiratory gated radiotherapy: Local experience
Speaker invited

12:30
Panel discussion and cases

13:00
Lunch break
Keynote lecture

14:00
Clinical trial on molecular targeting agent: What is right and what is wrong?
Francis A. Shepherd, MD

Session IV: Gene signature and biomarkers
14:40
Gene signature for chemotherapy
Giorgio V. Scagliotti, MD, PhD

15:05 Metagene or magic gene
David Harpole, MD

15:30
Clinical application of biomarker in management of NSCLC
Speaker invited

15:55
Coffee break

Session V: Stage III disease
16:15
Optimal radiotherapy for stage III NSCLC
Speaker invited

16:40
Optimal combined modality for stage III NSCLC
Wilfrried Eberhardt, MD

17:05
Adjourn
Saturday 4 September 2010

Session VI: State of the art in chemotherapy
8:30
Novel development in cytotoxic chemotherapy
Speaker invited

8:55
Combination of chemotherapy with molecular target therapy: A good idea that is not so good
Tony Mok, MD

9:20
Patient selection for maintenance therapy
Speaker invited

Session VII: Novel targets
9:35
MAGE A3
Speaker invited

9:50
ELM-4 ALK
Tetsuya Mitsudomi, MD

10:05
IGF-R
Speaker invited

10:20
Irreversible EGFR TKI
Speaker invited

10:45
Vascular disrupting agent and VEGF TKIs
Nick Pavlakis, MD

11:00
Coffee break

Session VIII: State-of-the-art diagnosis
11:30
Florescence bronchoscopy and pleuroscopy for diagnosis of lung cancer
Speaker invited

11:55
PET-Scan, MRI, or CT scan: Which is a better tool for early/late stage NSCLC?
Speaker invited

12:05
Global view on first line management of advanced NSCLC
Speaker invited

12:40
Panel discussion and cases

13:15
Lunch break

Session IX: The unfinished EGFR story
14:15
Cost-effectiveness of EGFR TKI
Gilberto Lopes, MD

14:30
Detecting EGFR mutation in plasma: DHPLC
Speaker invited

14:45
Detecting EGFR mutation in plasma: Digital PCR
Speaker invited

15:00
EGFR TKI resistance
Lu Shun, MD

15:15
Pharmacokinetics of EGFR TKI and treatment outcome
Speaker invited

15:30
Coffee break

Session X: Research and development
15:50
The art and science of phase I study
Speaker invited

16:10
Getting published in a high impact journal
Speaker invited

16:20
Current status of lung cancer research in Asia
Sumitra Thongprasert, MD

Current status of lung cancer research in China
YL-Long Wu, MD

Current status of lung cancer research in Japan
Speaker invited

17:00
Closing remarks

Kontakt: meetings@imedex.com

Web: http://www.imedex...Open5_5_2010&u

  • Sdílejte na:
    • Facebook
    • Twitter
    • Del.icio.us
    • Digg
    • Google
    • Reddit
    • StumbleUpon
    • Live

Podpora ČOS

Podpora Linkos.cz 

Děkujeme za podporu Linkos.cz! 

I my podporujeme 

Mezi členy ČOS je mnoho DOBRÝCH ANDĚLŮ, kteří přispívají rodinám, jež se vinou nemoci dostali do finanční tísně, ale také těch, kteří zprostředkují pomoc nadace DOBRÝ ANDĚL svým pacientům.